Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928029 | 0.84 | SMG1 (0.43) | HTR6DRD2HTR2APRKD1 | |
| SCHEMBL6927160 | 0.84 | DRD2 (0.43) | HTR6DRD2DRD3HTR2CDRD4 | |
| SCHEMBL6926804 | 0.84 | TRPA1 (0.39) | DRD2DRD3DRD4HTR2APRKD1 | |
| SCHEMBL6923588 | 0.83 | PIK3C3 (0.40) | DRD2DRD3DRD4PRKD1 | |
| SCHEMBL6924877 | 0.83 | PIK3C3 (0.38) | PARP1PRKD1 | |
| SCHEMBL6921236 | 0.83 | DRD2 (0.38) | PIM1DRD2DRD3DRD4PARP1 | |
| SCHEMBL13648725 | 0.82 | DRD2 (0.45) | PIM1HTR6SYKDRD2DRD3 | |
| SCHEMBL6925301 | 0.82 | MTOR (0.45) | DRD2DRD3 | |
| SCHEMBL6928150 | 0.82 | SMG1 (0.45) | DRD2DRD3 | |
| SCHEMBL6927463 | 0.82 | KDM4E (0.40) | HTR6HTR2APRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | PIM1 4661/4885HTR6 103/4885SYK 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.